Amgen still buy, Jefferies says

Amgen was maintained by Jefferies & Co. Inc. analyst Adam A. Walsh at a buy rating and a $96 price target after the company released interim results for a long-term, open-label study of AMG 531 in patients with immune thrombocytopenic purpura at a medical conference showing the drug stimulated platelet production and was well-tolerated. There are two phase 3 trials ongoing, and results are expected in the second half of 2006. Shares of the Thousand Oaks, Calif., biotechnology company were unchanged at $77.46 on volume of 8,209,394 shares versus the three-month running average of 8,198,450 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.